KLG Stock +78.58% In 3 Months Since We Picked KLG Stock +78.58% In 3 Months Since We Picked Unlock All Top Buy Picks
NASDAQ:CNAT
Delisted

Conatus Pharmaceuticals Inc. Stock Price (Quote)

$0.255
+0 (+0%)
At Close: May 27, 2022

Range Low Price High Price Comment
30 days $0.255 $0.255 Friday, 27th May 2022 CNAT stock ended at $0.255. During the day the stock fluctuated 0% from a day low at $0.255 to a day high of $0.255.
90 days $0.238 $0.275
52 weeks $0.203 $1.23

Historical Conatus Pharmaceuticals Inc. prices

Date Open High Low Close Volume
Mar 17, 2022 $0.255 $0.255 $0.255 $0.255 0
Mar 16, 2022 $0.255 $0.255 $0.255 $0.255 0
Mar 15, 2022 $0.255 $0.255 $0.255 $0.255 0
Mar 14, 2022 $0.255 $0.255 $0.255 $0.255 0
Mar 11, 2022 $0.255 $0.255 $0.255 $0.255 0
Mar 10, 2022 $0.255 $0.255 $0.255 $0.255 0
Mar 09, 2022 $0.255 $0.255 $0.255 $0.255 0
Mar 08, 2022 $0.255 $0.255 $0.255 $0.255 0
Mar 07, 2022 $0.255 $0.255 $0.255 $0.255 0
Mar 04, 2022 $0.255 $0.255 $0.255 $0.255 0
Mar 03, 2022 $0.255 $0.255 $0.255 $0.255 0
Mar 02, 2022 $0.255 $0.255 $0.255 $0.255 0
Mar 01, 2022 $0.240 $0.275 $0.240 $0.255 1 385 449
Feb 28, 2022 $0.240 $0.241 $0.238 $0.239 161 999
Feb 25, 2022 $0.239 $0.254 $0.223 $0.247 392 783
Feb 24, 2022 $0.220 $0.239 $0.205 $0.235 208 455
Feb 23, 2022 $0.239 $0.239 $0.220 $0.230 192 745
Feb 22, 2022 $0.230 $0.239 $0.220 $0.229 434 725
Feb 18, 2022 $0.240 $0.244 $0.230 $0.233 441 691
Feb 17, 2022 $0.245 $0.245 $0.232 $0.237 578 828
Feb 16, 2022 $0.240 $0.245 $0.225 $0.230 890 180
Feb 15, 2022 $0.222 $0.240 $0.222 $0.237 800 874
Feb 14, 2022 $0.240 $0.242 $0.221 $0.224 817 376
Feb 11, 2022 $0.243 $0.250 $0.235 $0.238 985 317
Feb 10, 2022 $0.250 $0.260 $0.240 $0.254 1 215 630
Click to get the best stock tips daily for free!

About Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals. Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase II clinical trials for the treatment of liver cirrhosis, acute-on-chronic liver failure, post-orthotopic liver transplant as a result of hepatitis C virus infection with sust... CNAT Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT